
    
      OBJECTIVES:

        -  Evaluate the response rate of patients with incurable salivary gland cancer treated with
           gemcitabine.

        -  Evaluate the time to progression and toxicity of this therapy in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive gemcitabine IV for 30 minutes on days 1, 8, and 15 of each 28 day course.
      Patients receive a minimum of 2 courses of treatment. Patients may continue treatment in the
      absence of disease progression or unacceptable toxicity.

      Patients are followed every 2 months.

      .
    
  